Alzamend Neuro, Inc. (ALZN)
1.13
+0.01
(+0.89%)
USD |
NASDAQ |
Oct 23, 16:00
1.09
-0.04
(-3.54%)
Pre-Market: 09:13
Alzamend Neuro Enterprise Value : -2.138M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | -2.138M |
| October 22, 2026 | -2.187M |
| October 21, 2026 | -1.559M |
| October 20, 2026 | -1.318M |
| October 19, 2026 | -1.173M |
| October 16, 2026 | -1.318M |
| October 15, 2026 | -1.414M |
| October 14, 2026 | -1.077M |
| October 13, 2026 | -1.077M |
| October 12, 2026 | -1.270M |
| October 09, 2026 | -1.125M |
| October 08, 2026 | -1.125M |
| October 07, 2026 | -0.9802M |
| October 06, 2026 | -0.9802M |
| October 05, 2026 | -0.7872M |
| October 02, 2026 | -0.9802M |
| October 01, 2026 | -1.246M |
| September 30, 2026 | 0.7571M |
| September 29, 2026 | 1.191M |
| September 28, 2026 | 0.7571M |
| September 25, 2026 | 1.240M |
| September 24, 2026 | 1.191M |
| September 23, 2026 | 1.770M |
| September 22, 2026 | 1.770M |
| September 21, 2026 | 1.770M |
| Date | Value |
|---|---|
| September 18, 2026 | 1.529M |
| September 17, 2026 | 1.288M |
| September 16, 2026 | 1.240M |
| September 15, 2026 | 0.9983M |
| September 14, 2026 | 0.8536M |
| September 11, 2026 | 0.7088M |
| September 10, 2026 | 0.6123M |
| September 09, 2026 | 0.5158M |
| September 08, 2026 | 0.5158M |
| September 04, 2026 | 0.4193M |
| September 03, 2026 | 0.6123M |
| September 02, 2026 | 0.6123M |
| September 01, 2026 | 0.3073M |
| August 31, 2026 | 0.1297M |
| August 28, 2026 | 0.4193M |
| August 27, 2026 | 0.4434M |
| August 26, 2026 | 0.4675M |
| August 25, 2026 | 0.1297M |
| August 24, 2026 | -0.1116M |
| August 21, 2026 | -0.0633M |
| August 20, 2026 | 0.2745M |
| August 19, 2026 | -0.2563M |
| August 18, 2026 | -0.2563M |
| August 17, 2026 | 0.0332M |
| August 14, 2026 | -0.1116M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.514B |
| Alnylam Pharmaceuticals, Inc. | 29.64B |
| Anika Therapeutics, Inc. | 273.50M |
| Savara, Inc. | 724.16M |
| Vericel Corp. | 2.108B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.027M |
| Total Expenses (Quarterly) | 3.027M |
| EPS Diluted (Quarterly) | -0.6759 |
| Earnings Yield | -202.5% |
| Normalized Earnings Yield | -202.48 |